NCRI Staff

NCRI - The drug "Sinopar", which in 2016 was purchased by the patients with insurance coverage for 60 thousand Toman, has now risen to more than 600 thousand Toman.

The state-run Tasnim news agency affiliated to terrorist Quds force on Friday November 9, and in a factional feud against Hassan Rouhani's government, wrote: “For several weeks, the price of Sinopar (tripartite hormone - the generic name of the drug), which is involved in severe fractures and osteoporosis, and especially applied in the spine injury, has increased to more than 600 thousand Toman.

Unfortunately, the insurance cut off the coverage of this drug and the drug in the free (black) market costs 650 thousand Toman, while with the insurance coverage it was 65 thousand Toman in the past.”

“Insurers have made their work easy and never held accountable to their defective performance, which causes a lot of suffering to patients, and ultimately it is the patient who has to face hard times ahead of him, because drug and insurance managers do not care to respond,” Tasnim wrote.

“Now in the new 12th government ... we are witnessing some silent drug-related changes in the country that, with the cry of patients, some of these drug problems are communicated, while health and safety managers are currently in favor of silence fasting.”

Pin It

Iran news in brief


Iran Protests

“Iran Uprising - International Call for Release of Detainees” - Conference - February 9, 2018

NCRI on Twitter

Lord Clarkes seeks global action to save the lives of Iran protesters


1988 massacre in Iran

The untold story of the 1988 Massacre in Iran


Assist us in our campaign for
freedom, democracy and human rights